<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011997</url>
  </required_header>
  <id_info>
    <org_study_id>FAH-GZU-001</org_study_id>
    <nct_id>NCT02011997</nct_id>
  </id_info>
  <brief_title>Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion</brief_title>
  <acronym>cVATS</acronym>
  <official_title>Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Prospective, open-label, parallel, multi-center, Phase III randomized trial to
      evaluate the efficacy and safety of video-assisted thoracoscopic segmentectomy versus
      Lobectomy in treating patients with Lung adenocarcinoma in situ or with microinvasion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lobectomy has long been considered the standard procedure for early-stage lung cancer, and
      minimally invasive techniques have been demonstrated to be associated with superior outcomes
      compared with lobectomy by thoracotomy. the us of segmentectomy is under investigation for
      selected patients with small tumors, and the use of minimally invasive strategies is
      applicable as well.

      This nationwide, multicenter, prospective, randomized open phase III study of cVATS (complete
      Video-assisted Thoracoscopic Surgery) segmentectomy versus Lobectomy for stage IA non-small
      cell lung cancer (NSCLC) patients with Lung adenocarcinoma in situ or with microinvasion, is
      aiming to evaluate the relapse free survival and 5 year overall survival (OS) rate of two
      types of surgery. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients undergo cVATS lobectomy.

        -  Arm II: Patients undergo cVATS segmentectomy.

      Patients will be followed up every 3 months within the first year, and annually for 5 years
      postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>From date of randomization until the date of first documented relapse or metastasis, whichever came first, assessed up to 5 years</time_frame>
    <description>Compare the relapse-free survival (RFS) of patients with lung adenocarcinoma in situ or microinvasion undergoing cVATS segmentectomy vs lobectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-year survival rate</measure>
    <time_frame>participants are followed until death or up to 5 years</time_frame>
    <description>Compare the 5-year survival rate of patients undergoing cVATS segmentectomy vs lobectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complication</measure>
    <time_frame>0 to 3 months postoperatively</time_frame>
    <description>Compare the postoperative complication rate of patients undergoing cVATS segmentectomy vs lobectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary function</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>to evaluate the pulmonary function as measured by expiratory flow rate of the two groups 6 months postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>0 to 6 months postoperative</time_frame>
    <description>To evaluate the quality of life (QoL) of these patients, as measured by questionnaire of FACT-L (4th edition) and LCSS (Lung Cancer Symptom Scale)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Non-small Cell Lung Cancer Stage I</condition>
  <condition>Lung Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>segmentectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo cVATS (complete Video-assisted Thoracoscopic Surgery) segmentectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lobectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo cVATS lobectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>patients undergo cVATS segmentectomy</intervention_name>
    <arm_group_label>segmentectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Patients undergo cVATS lobectomy</intervention_name>
    <arm_group_label>Lobectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Preoperative criteria: peripheral non-small cell lung cancer, no larger than 2 cm in
        maximal diameter, no lymph node metastasis, FEV1%&gt;50% (FEV1: Forced Expiratory Volume in 1
        second);

        Preoperative imaging:pure ground-glass or mixed ground-glass nodules (part-solid, solid
        areas &lt; 0.5cm);

        Follow-up duration last 3 months or more, HRCT (HRCT: high-resolution computed tomography)
        lesion maximum diameter was measured three times and took the average, meet the criteria of
        clinical surgical indications;

        Intraoperative criteria: histologically confirmed NSCLC, adenocarcinoma in situ or with
        microinvasion;

        No prior ipsilateral thoracotomy;

        No prior anti-neoplastic therapy;

        EOCG Performance status 0-2;

        Sufficient organ functions;

        Written informed consent.

        Exclusion Criteria:

        Active bacterial or fungous infection;

        Simultaneous or prior (within the past 5 years) other malignant disease;

        Interstitial pneumonitis, pulmonary fibrosis, or severe COPD (COPD: chronic obstructive
        pulmonary disease);

        Abnormal Psychosis;

        Uncontrollable diabetes mellitus;

        History of severe cardiovascular disease;

        Any condition which, in the opinion of the investigator might interfere with the evaluation
        of the objective.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianxing He, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianxing He, MD</last_name>
    <phone>83062810</phone>
    <email>drjianxinghe@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital Zhejiang University colleague of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship hospital</name>
      <address>
        <city>Bejing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Van Schil PE, Asamura H, Rusch VW, Mitsudomi T, Tsuboi M, Brambilla E, Travis WD. Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. Eur Respir J. 2012 Feb;39(2):478-86. doi: 10.1183/09031936.00027511. Epub 2011 Aug 4. Review.</citation>
    <PMID>21828029</PMID>
  </reference>
  <reference>
    <citation>Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3.</citation>
    <PMID>7677489</PMID>
  </reference>
  <reference>
    <citation>Koike T, Togashi K, Shirato T, Sato S, Hirahara H, Sugawara M, Oguma F, Usuda H, Emura I. Limited resection for noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination. Ann Thorac Surg. 2009 Oct;88(4):1106-11. doi: 10.1016/j.athoracsur.2009.06.051.</citation>
    <PMID>19766789</PMID>
  </reference>
  <reference>
    <citation>Yan TD, Black D, Bannon PG, McCaughan BC. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. J Clin Oncol. 2009 May 20;27(15):2553-62. doi: 10.1200/JCO.2008.18.2733. Epub 2009 Mar 16. Review.</citation>
    <PMID>19289625</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2013</study_first_posted>
  <last_update_submitted>December 13, 2013</last_update_submitted>
  <last_update_submitted_qc>December 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Jianxing He</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma in Situ</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

